ProPhase Labs, Inc. Business Acquisition, Pro Forma Net Income (Loss)
ProPhase Labs, Inc. (PRPH) reported Business Acquisition, Pro Forma Net Income (Loss) of $6.13 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-03-29
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was $10.59M.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-09-30 was -$4.02M.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-12-31 was -$1.26M.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2020-09-30 was -$764.00K.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for fiscal 2022 was $6.13M, a 0.00% change from fiscal 2021.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for fiscal 2021 was $6.13M.
- ProPhase Labs, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$3.68M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $6.13M 10-K · filed 2023-03-29 | |||
| 2021-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.57M derived: sum of 2 quarters · filed 2022-03-31 | $6.13M 10-K · filed 2022-03-31 | |
| 2021-09-30 | -$4.02M 10-Q · filed 2021-11-12 | -$4.45M 10-Q · filed 2021-11-12 | ||
| 2020-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$2.02M derived: sum of 2 quarters · filed 2022-03-31 | -$3.68M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$764.00K 10-Q · filed 2021-11-12 | -$2.42M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |